Management of fear of radiation exposure in carers of outpatients treated with iodine-131

Annals of Nuclear Medicine

Volumn 26, Issue 6, 2012, Pages 508-514

  Calais, Phillipe J ^a   Page, Andrew C ^a   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Radioactivity exposure; Radiophobia; Relative risk

Indexed keywords

RITUXIMAB; RITUXIMAB I 131; UNCLASSIFIED DRUG;

ARTICLE; FEAR; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OUTPATIENT; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION HAZARD; RADIOIMMUNOTHERAPY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CAREGIVERS; ENVIRONMENTAL EXPOSURE; FEAR; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA; OUTPATIENTS; RADIOIMMUNOTHERAPY; RISK ASSESSMENT;

EID: 84864710166     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0603-6     Document Type: Article

References (20)

1. ICRP Publication 94. Release of patients after therapy with unsealed radionuclides. Ann ICRP 2004;34(2).
2. IAEA Safety Series No. 115. International Basic Safety Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources. Vienna, 1996.
3. ARPANSA RPS4. Discharge of Patients Undergoing Treatment with Radioactive Substances. Yalambie, Victoria, Australia, 2002.
4. Lindell B. The risk philosophy of radiation protection. Radiat Prot Dosimetry. 1996;68:157-63. (Pubitemid 27010943)
5. Drottz-Sjoberg BM, Persson L. Public reaction to radiation: fear, anxiety, or phobia? Health Phys. 1993;64:223-31.
6. Kinuya S. A nuclear power plant accident in Fukushima: what should we do? Ann Nucl Med. 2012;26:113-4.
7. Calais PJ, Turner JH. Outpatient iodine-131-rituximab radioimmunotherapy of non-hodgkin lymphoma - a study in safety. Clin Nucl Med. 2012.
8. Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med. 2012. Epub 2012/01/10.
9. 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117:45-52.
10. 131I-rituximab: The INITIAL Study. ASH Meeting, 2011 Abst 3719.
11. ARPANSA. Ionizing radiation and health - fact Sheet 17. Yalambie, VIC, Australia, 2004.
12. Gould DM. A disease of the atomic age; radiation phobia. Med Times. 1959;87:59-65.
13. Wigg DR. Radiation: facts, fallacies and phobias. Australas Radiol. 2007;51:21-5. (Pubitemid 46087987)
14. Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567-8.
15. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211-8.
16. Ilic D. The role of the internet on patient knowledge management, education, and decision-making. Telemed J E Health. 2010;16:664-9.
17. Eysenbach G, Powell J, Kuss O, Sa ER. Empirical studies assessing the quality of health information for consumers on the world wide web: a systematic review. JAMA. 2002;287: 2691-700. (Pubitemid 34533548)
18. Stevenson FA, Kerr C, Murray E, Nazareth I. Information from the Internet and the doctor-patient relationship: the patient perspective - a qualitative study. BMC Fam Pract. 2007;8:47.
19. Claringbold PG, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:302-11.
20. Higashi T, Kudo T, Kinuya S. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. Ann Nucl Med. 2012;26:99-112.